Savara (SVRA) Competitors $2.58 +0.03 (+1.18%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.58 +0.00 (+0.19%) As of 07/25/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVRA vs. JANX, ETNB, EVO, VERA, ANIP, BHVN, TVTX, EWTX, COGT, and SRPTShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Janux Therapeutics (JANX), 89BIO (ETNB), Evotec (EVO), Vera Therapeutics (VERA), ANI Pharmaceuticals (ANIP), Biohaven (BHVN), Travere Therapeutics (TVTX), Edgewise Therapeutics (EWTX), Cogent Biosciences (COGT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Savara vs. Its Competitors Janux Therapeutics 89BIO Evotec Vera Therapeutics ANI Pharmaceuticals Biohaven Travere Therapeutics Edgewise Therapeutics Cogent Biosciences Sarepta Therapeutics Savara (NASDAQ:SVRA) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment. Do insiders and institutionals believe in SVRA or JANX? 87.9% of Savara shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 8.1% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is SVRA or JANX more profitable? Janux Therapeutics' return on equity of -9.29% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets SavaraN/A -65.88% -52.35% Janux Therapeutics N/A -9.29%-8.89% Which has better earnings and valuation, SVRA or JANX? Janux Therapeutics has higher revenue and earnings than Savara. Janux Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSavaraN/AN/A-$95.88M-$0.48-5.38Janux Therapeutics$10.59M145.05-$68.99M-$1.36-19.09 Do analysts rate SVRA or JANX? Savara presently has a consensus price target of $5.60, indicating a potential upside of 117.05%. Janux Therapeutics has a consensus price target of $91.89, indicating a potential upside of 253.96%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Savara.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Savara 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08 Which has more risk and volatility, SVRA or JANX? Savara has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the S&P 500. Does the media prefer SVRA or JANX? In the previous week, Janux Therapeutics had 3 more articles in the media than Savara. MarketBeat recorded 7 mentions for Janux Therapeutics and 4 mentions for Savara. Janux Therapeutics' average media sentiment score of 1.27 beat Savara's score of 0.75 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryJanux Therapeutics beats Savara on 12 of the 15 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$440.73M$2.50B$5.70B$9.50BDividend YieldN/A1.75%4.69%4.01%P/E Ratio-5.379.0528.1020.06Price / SalesN/A592.38428.7189.11Price / CashN/A165.2136.2258.56Price / Book2.585.168.665.87Net Income-$95.88M$30.99M$3.25B$258.55M7 Day Performance14.16%7.74%4.22%3.73%1 Month Performance16.74%16.27%10.51%11.75%1 Year Performance-42.15%-1.88%34.40%18.02% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara1.8402 of 5 stars$2.58+1.2%$5.60+117.1%-43.7%$440.73MN/A-5.3720JANXJanux Therapeutics2.471 of 5 stars$26.08-1.2%$91.89+252.3%-39.3%$1.56B$10.59M0.0030ETNB89BIO1.8565 of 5 stars$10.11-3.6%$26.43+161.4%-0.7%$1.53BN/A0.0040EVOEvotec2.028 of 5 stars$3.69-13.4%$5.93+60.8%-9.6%$1.51B$862.40M0.004,827Gap UpHigh Trading VolumeVERAVera Therapeutics4.2816 of 5 stars$22.79-1.1%$65.00+185.2%-40.8%$1.47BN/A0.0040Positive NewsANIPANI Pharmaceuticals3.8572 of 5 stars$65.41-1.3%$78.88+20.6%+8.8%$1.44B$614.38M-51.50600BHVNBiohaven2.3164 of 5 stars$13.81-1.7%$58.46+323.5%-66.4%$1.43BN/A-1.47239Trending NewsTVTXTravere Therapeutics2.961 of 5 stars$15.82-1.8%$32.14+103.2%+56.8%$1.43B$233.18M0.00460Upcoming EarningsEWTXEdgewise Therapeutics1.6647 of 5 stars$13.39-1.1%$40.00+198.7%-24.6%$1.42BN/A0.0060COGTCogent Biosciences3.5614 of 5 stars$12.30-1.5%$18.70+52.0%+30.9%$1.42BN/A-6.6880SRPTSarepta Therapeutics4.6958 of 5 stars$13.32-5.3%$54.33+307.9%-91.9%$1.38B$1.90B0.001,372Trending NewsAnalyst DowngradeGap DownHigh Trading Volume Related Companies and Tools Related Companies JANX Alternatives ETNB Alternatives EVO Alternatives VERA Alternatives ANIP Alternatives BHVN Alternatives TVTX Alternatives EWTX Alternatives COGT Alternatives SRPT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVRA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SVRA Stock Alerts